Access Program Information
<p>Primary Objectives:</p>
<p>- Provide <em><strong>palliative therapy</strong></em> with 131I-MIBG for patients with advanced <strong>neuroblastoma, pheochromocytoma, or paraganglioma.</strong></p>
<p>- Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with <strong>refractory neuroblastoma, pheochromocytoma, or paraganglioma.</strong></p>